Repligen stock climbed 3.4% in pre-open trading after the company reported second-quarter results that exceeded analyst expectations and updated its outlook for the year. The bioprocessing equipment and consumables provider posted adjusted earnings per share of $0.54, beating the consensus estimate of $0.45 by $0.09. Revenue for the quarter was $204.1 million, representing nearly a 12% increase year-over-year and coming in ahead of analyst forecasts.
Quarterly performance and profitability
The quarter showed broad-based strength, with adjusted EBITDA reported at $43.77 million, topping analyst estimates of $38.3 million by more than 14%. The company characterized the results as a combination of accelerating organic growth and continued execution across its portfolio.
Management perspective
"We were very pleased to deliver 13% organic growth in the second quarter, reflecting sequential acceleration and continued market outperformance. This reflects the strength and diversification of our portfolio and our disciplined execution. The order momentum from the first quarter continued into the second quarter. Our strong first half results and improved line of sight to the second half give us the confidence to increase our full year guidance."
The comment, provided by CEO Olivier Loeillot, emphasizes the company's reported organic growth rate and the continuity of order flow from one quarter to the next as the basis for raising full-year expectations.
Guidance and deal activity
Alongside the quarterly release, Repligen issued an updated full-year 2026 adjusted EPS range of $2.03 to $2.09, compared with the prior consensus of $2.00. The results and lifted guidance arrive while the company pursues a transformational acquisition: a previously announced $1.5 billion agreement to acquire BioLife Solutions, a cell processing developer. Management and the release highlight that new modalities are expected to represent approximately 25% of pro forma revenue.
Analyst reaction
The strong quarter and outlook prompted Benchmark analyst Robert Wasserman to upgrade Repligen from Hold to Buy and set a price target of $185. That upgrade, together with the earnings beat and the guidance increase, contributed to the early trading strength.
Market context
Today's broader market environment was mixed and does not fully account for Repligen's pre-market performance. The S&P 500 was up roughly 0.1%, the Dow Jones gained about 0.9%, while the NASDAQ was slightly negative at around -0.6% on the same morning. Those index moves suggest RGEN's pre-market advance was driven primarily by company-specific developments rather than general market momentum.
The bioprocessing sector has shown improving sentiment recently, with observations from Danaher indicating a pickup in bioprocessing demand as pharmaceutical and biotechnology companies increase spending after a period of reduced research activity and inventory adjustments. That backdrop likely reinforced investor reception to Repligen's results and strategic positioning.
Why the stock moved
Investors had multiple catalysts in the pre-market session: a clear earnings beat on EPS and EBITDA, revenue growth, an upward revision to full-year guidance, an analyst upgrade, and the near-term strategic impact of a sizable acquisition that increases exposure to new modalities. Collectively, those elements supplied several reasons for buyers to bid the stock higher ahead of the opening bell.
Bottom line
Repligen's second-quarter results delivered stronger-than-expected profitability and revenue, management signaled confidence in the remainder of the year with raised guidance, and an acquisition enlarges the firm's addressable market in new modalities. Those factors combined to drive the stock's pre-market rally.